

# Contents

## 1 Introduction and Historical Background: Pediatric Hodgkin Lymphoma

S.S. Donaldson

1.1	The Way It Was . . . . .	1
1.2	Lessons from the Children . . . . .	3
1.3	The Hidden Secrets – The Discovery of Late Effects . . . . .	3
1.4	Current Optimal Management . . . . .	4
	References . . . . .	4

## 2 Biology and Pathology of Hodgkin's Disease

R.E. Hutchinson and A. Uner

2.1	History of Hodgkin's Disease Pathologic Classification . . . . .	7
2.2	Lineage of Hodgkin Reed-Sternberg cells; B-cell phenotype . . . . .	9
2.3	Some Evidence of Antigen-Presenting Function . . . . .	10
2.4	Apoptosis . . . . .	10
2.5	NF-kappaB . . . . .	11
2.6	Jak/STAT Pathways . . . . .	12
2.7	Tumor Necrosis Factor Receptor (TNFR) Family . . . . .	12
2.8	Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) . . . . .	12
2.9	Cytokines and Chemokines . . . . .	13
2.10	Cytogenetics . . . . .	14
2.11	Gene Profile . . . . .	14
2.12	Association with EBV . . . . .	14
2.13	Pathology of Classical Hodgkin Lymphoma . . . . .	16
2.14	Immunophenotype of Classical HRS cells . . . . .	17
2.15	Flow Cytometry . . . . .	18

2.16	Histologic Classification of CHL . . . . .	19
2.16.1	Nodular Sclerosis HL . . . . .	19
2.16.2	Mixed Cellularity HL . . . . .	20
2.16.3	Nodular Lymphocyte Rich CHL . . . . .	21
2.16.4	Lymphocyte Depleted HL . . . . .	22
2.17	Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) . . . . .	22
2.18	Hodgkin Lymphoma in the Setting of HIV Infection . . . . .	23
2.19	Bone Marrow Involvement and Histologic Staging . . . . .	23
2.20	Pathology of Relapse and Second Malignancy . . . . .	24
2.21	Differential Diagnosis of HL . . . . .	25
	References . . . . .	27

## 3 Treatment of Pediatric Hodgkin Lymphoma

M.M. Hudson, C. Schwartz, and L.S. Constine

3.0	Introduction . . . . .	35
3.1	Clinical Presentation . . . . .	36
3.1.1	Systemic Symptoms . . . . .	37
3.1.2	Laboratory Evaluation . . . . .	37
3.1.3	Immunologic Status . . . . .	38
3.2	Differential Diagnosis . . . . .	39
3.3	Diagnostic Evaluation and Staging . . . . .	40
3.4	Prognostic Factors . . . . .	43
3.5	Combination Chemotherapy . . . . .	45
3.6	Chemotherapy Alone Versus Combined Modality Therapy . . . . .	49
3.7	Risk-Adapted Therapy . . . . .	51
3.7.1	Treatment of Low-Risk Disease . . . . .	51
3.7.2	Treatment of Intermediate- and High-Risk Disease . . . . .	53
3.8	Principles of Radiation Therapy . . . . .	54
3.8.1	Volume Considerations . . . . .	56
3.8.2	Dose Considerations . . . . .	58
3.8.3	Energy . . . . .	59

3.9	Summary Recommendations for Primary Disease/Selection of Therapy . . . . .	59
3.10	Acute Effects of Therapy . . . . .	59
3.10.1	Chemotherapy Side-Effects. . . . .	59
3.10.2	Radiation Side-Effects . . . . .	61
3.11	Future Directions . . . . .	61
References	. . . . .	61

## 4 Treatment of Relapsed/Refractory Hodgkin Lymphoma

T.M. Trippett and A. Chen

4.1	Introduction . . . . .	67
4.2	Strategies for Re-induction . . . . .	67
4.2.1	Role of Re-induction Chemotherapy . .	68
4.2.2	Standard Re-induction with ICE . . . .	68
4.2.3	Re-induction with Ifosfamide/Vinorelbine (IV) . . . . .	69
4.3	High-Dose Therapy. . . . .	70
4.3.1	Immunomodulation as a Therapeutic Strategy to Augment High-Dose Therapy . . . . .	71
4.3.2	Reduced-Intensity/Non-myeloablative Allogeneic Stem cell Transplantation. .	72
4.4	Salvage Strategies Following Transplantation . . . . .	72
4.4.1	Combination Chemotherapy with Gemcitabine/Vinorelbine (GEM/VRB) .	73
4.4.2	Molecular Targeting of the NF- $\kappa$ B Pathway. . . . .	74
4.4.2.1	Activation of NF- $\kappa$ B. . . . .	74
4.4.2.2	Inhibition of NF- $\kappa$ B Through Proteasome Inhibition . . . . .	75
4.4.2.3	Adult Clinical Trials . . . . .	76
4.4.2.4	Pediatric Clinical Trials. . . . .	77
4.4.2.5	Novel Retrieval Strategies Incorporating Proteasome Inhibition with Bortezomib . .	77
4.4.3	Targeted Immunotherapy Strategies. . .	77
4.4.3.1	Epstein-Barr Virus Directed Therapy . . . . .	77
4.4.3.2	Monoclonal Antibodies Targeting Receptors Expressed in HL . . . .	78
4.4.3.3	Radiolabeled Immunoglobulin Therapy in HL . . . . .	79
4.5	Future Considerations . . . . .	79
References	. . . . .	79

## 5 Non-Hodgkin's Lymphoma: Introduction and Historical Background

S.B. Murphy

5.1	Introduction . . . . .	85
5.2	The Early Era, Pre-1970 . . . . .	86
5.3	The Latter Era, Post-1970s . . . . .	86
References	. . . . .	88

## 6 Biology and Pathology of Pediatric Non-Hodgkin Lymphoma

S.L. Perkins and S.W. Morris

6.1	Introduction . . . . .	91
6.2	Non-Hodgkin Lymphoma . . . . .	91
6.3	Pathologic Analysis. . . . .	93
6.3.1	Morphology . . . . .	93
6.3.2	Immunophenotypic Analysis. . . . .	94
6.3.3	Molecular and Cytogenetic Analysis . .	95
6.3.4	WHO Classification of Hematolymphoid Tumors. . . . .	100
6.4	Molecular Pathogenesis of Pediatric NHL . .	101
6.5	Burkitt Lymphomas . . . . .	101
6.5.1	Pathology . . . . .	101
6.5.2	Biology and Molecular Mechanisms .	104
6.6	Diffuse Large B-Cell Lymphomas . . . . .	107
6.6.1	Pathology . . . . .	107
6.6.2	Biology and Molecular Mechanisms .	109
6.7	Anaplastic Large-Cell Lymphoma . . . . .	112
6.7.1	Pathology . . . . .	112
6.7.2	Biology and Molecular Mechanisms .	117
6.8	Lymphoblastic Lymphoma. . . . .	119
6.8.1	Pathology . . . . .	119
6.8.2	Biology and Molecular Mechanisms .	121
References	. . . . .	127

## 7 B-Cell Lymphoma/Burkitt Lymphoma

I. Magrath

7.1	Introduction . . . . .	142
7.2	Diagnosis and Imaging . . . . .	142
7.2.1	Burkitt Lymphoma . . . . .	142
7.2.2	Diffuse Large B-cell Lymphoma . . .	143
7.2.3	Burkitt-like Lymphoma . . . . .	144
7.2.4	HIV-Associated B-cell Lymphomas . .	144
7.2.5	Imaging Studies . . . . .	144

7.3	<b>Clinical Features</b> . . . . .	146
7.4	<b>Staging</b> . . . . .	148
7.4.1	Staging Procedures . . . . .	150
7.5	<b>Treatment</b> . . . . .	151
7.5.1	Early Studies in Africa . . . . .	151
7.5.2	Non-Cross-Resistant Drugs and Combination Therapy . . . . .	152
7.5.3	Therapy Directed Towards CNS Disease . . . . .	154
7.5.4	Early Studies in the USA . . . . .	154
7.5.5	Comparison with Leukemia Treatment . . . . .	155
7.5.6	Critical Components of Modern Treatment Protocols . . . . .	155
7.5.6.1	Basic Drugs . . . . .	155
7.5.6.2	High-Dose MTX . . . . .	156
7.5.6.3	The Role of Additional Drugs . . . . .	156
7.5.6.4	Dose Density . . . . .	157
7.5.6.5	Risk Adaptation . . . . .	157
7.5.6.6	Prevention of CNS Disease . . . . .	159
7.5.6.7	Treatment of DLBCL with Different Regimens . . . . .	160
7.5.6.8	Role of Surgery . . . . .	160
7.5.6.9	Role of Radiation . . . . .	161
7.5.6.10	Tumor Lysis Syndrome . . . . .	162
7.6	<b>Prognostic Factors</b> . . . . .	163
7.6.1	Tumor Burden and Stage . . . . .	163
7.6.2	Rapidity of Response . . . . .	164
7.6.3	Age and Sex . . . . .	164
7.6.4	Histology . . . . .	164
7.6.5	Molecular Characteristics . . . . .	165
7.7	<b>Outcome</b> . . . . .	165
7.8	<b>Management of Relapse</b> . . . . .	166
7.9	<b>Follicle Center Cell and Marginal Zone Lymphomas</b> . . . . .	167
7.10	<b>Future Prospects</b> . . . . .	167
	<b>References</b> . . . . .	168

## 8 Anaplastic Large-Cell Lymphoma

A. Reiter

8.1	<b>Introduction</b> . . . . .	175
8.2	<b>Diagnosis and Imaging</b> . . . . .	177
8.3	<b>Clinical Features</b> . . . . .	178
8.4	<b>Staging</b> . . . . .	181
8.5	<b>Treatment and Outcome</b> . . . . .	181
8.5.1	Stratification of Treatment Intensity . . . . .	185
8.5.2	CNS Prophylaxis and CNS Therapy . . . . .	185
8.5.3	Role of Local Therapy Modalities and Pattern of Therapy Failure . . . . .	186
8.6	<b>Prognostic Factors</b> . . . . .	187
8.7	<b>Management of Relapse</b> . . . . .	189
8.8	<b>Future Prospects</b> . . . . .	190
	<b>References</b> . . . . .	192

## 9 Precursor B and Precursor T-Cell Lymphoblastic Lymphoma

J.T. Sandlund

9.1	<b>Introduction</b> . . . . .	199
9.2	<b>Diagnosis and Imaging</b> . . . . .	199
9.2.1	Diagnosis . . . . .	199
9.2.2	Imaging/Staging . . . . .	201
9.3	<b>Clinical Features</b> . . . . .	202
9.4	<b>Treatment</b> . . . . .	202
9.4.1	Initial Management . . . . .	202
9.4.2	Treatment Overview . . . . .	203
9.4.2.1	Limited Stage Disease . . . . .	203
9.4.2.2	Advanced Stage Disease . . . . .	204
9.4.2.3	Central Nervous System Prophylaxis and Treatment . . . . .	205
9.5	<b>Prognostic Factors</b> . . . . .	208
9.6	<b>Outcome</b> . . . . .	208
9.7	<b>Management of Relapse</b> . . . . .	208
9.8	<b>Future Prospects</b> . . . . .	208
	<b>References</b> . . . . .	210

## 10 Cutaneous T-Cell Lymphomas and Rare T-Cell Non-Hodgkin Lymphomas

M.E. Kadin

10.1	<b>Introduction</b> . . . . .	215
10.2	<b>Mycosis Fungoides and Sezary Syndrome</b> . . . . .	216
10.2.1	Clinical Features . . . . .	216
10.2.2	Pathology . . . . .	217
10.2.3	Immunophenotype . . . . .	218
10.2.4	Genetic Features . . . . .	218
10.2.5	Prognosis . . . . .	219
10.2.6	Therapy . . . . .	220
10.3	<b>CD30+ Cutaneous T-Cell Lymphomas Including Lymphomatoid Papulosis</b> . . . . .	221
10.4	<b>Lymphomatoid Papulosis</b> . . . . .	221
10.4.1	Clinical Features . . . . .	221
10.4.2	Pathology . . . . .	222
10.4.3	Immunophenotype . . . . .	223
10.4.4	Genetic Features . . . . .	223
10.4.5	Prognosis . . . . .	223
10.5	<b>Primary Cutaneous Anaplastic Large-cell Lymphoma</b> . . . . .	224
10.5.1	Clinical Features . . . . .	224
10.5.2	Pathology . . . . .	224
10.5.3	Differential Diagnosis . . . . .	224
10.5.4	Immunophenotype . . . . .	225
10.5.5	Genetic Features . . . . .	225
10.5.6	Therapy . . . . .	225

<b>10.6</b>	<b>Subcutaneous Panniculitis-like T-Cell Lymphoma</b> . . . . .	225
10.6.1	Clinical Features . . . . .	226
10.6.2	Pathology . . . . .	226
10.6.3	Immunophenotype . . . . .	226
10.6.4	Genetic Features . . . . .	227
10.6.5	Therapy . . . . .	227
<b>10.7</b>	<b>Hepatosplenic T-Cell Lymphoma</b> . . . . .	227
10.7.1	Clinical Features . . . . .	227
10.7.2	Pathology . . . . .	227
10.7.3	Immunophenotype . . . . .	227
10.7.4	Genetic Features . . . . .	227
10.7.5	Therapy . . . . .	228
<b>References</b>		228

## **11 Lymphoproliferative Disorders Related to Immunodeficiencies**

T.G. Gross and B. Shiramizu

<b>11.1</b>	<b>Introduction</b> . . . . .	233
<b>11.2</b>	<b>Epstein-Barr Virus</b> . . . . .	234
<b>11.3</b>	<b>Post-transplant Lymphoproliferative Disease</b> . . . . .	236
11.3.1	PTLD Following Blood or Marrow Transplantation . . . . .	239
11.3.2	PTLD Following Solid Organ Transplantation . . . . .	240
<b>11.4</b>	<b>HIV-Related Malignancies</b> . . . . .	242
<b>11.5</b>	<b>Lymphoproliferative Disease in Primary Immunodeficiencies</b> . . . . .	246
<b>11.6</b>	<b>Summary</b> . . . . .	250
<b>References</b>		250

## **12 Late Effects Following Lymphoma Treatment**

D.L. Friedman and A.T. Meadows

<b>12.1</b>	<b>Introduction</b> . . . . .	259
<b>12.2</b>	<b>Second Malignant Neoplasms</b> . . . . .	260
<b>12.3</b>	<b>Neurocognitive</b> . . . . .	261
<b>12.4</b>	<b>Cardiovascular</b> . . . . .	261
<b>12.5</b>	<b>Pulmonary</b> . . . . .	263
<b>12.6</b>	<b>Bone and Body Composition</b> . . . . .	264
<b>12.7</b>	<b>Endocrine</b> . . . . .	264
12.7.1	Thyroid Gland . . . . .	264
<b>12.8</b>	<b>Reproductive Endocrine</b> . . . . .	265
12.8.1	Male Gonadal Function . . . . .	265
12.8.2	Female Gonadal Function . . . . .	265
12.8.3	Reproduction . . . . .	266
<b>12.9</b>	<b>Dental</b> . . . . .	267
<b>12.10</b>	<b>Spleen</b> . . . . .	267
<b>12.11</b>	<b>Psychosocial</b> . . . . .	268
<b>12.12</b>	<b>Mortality</b> . . . . .	268
<b>12.13</b>	<b>Monitoring for Late Effects</b> . . . . .	269
<b>12.14</b>	<b>Research Challenges for Lymphoma Survivors</b> . . . . .	269
<b>12.15</b>	<b>Future Directions</b> . . . . .	273
<b>References</b>		274

<b>Subject Index</b> . . . . .	281
--------------------------------	-----

Pediatric Lymphomas

Weinstein, H.J.; Hudson, M.M.; Link, M.P. (Eds.)

2007, XII, 292 p. 56 illus., 52 illus. in color., Hardcover

ISBN: 978-3-540-20356-8